Publications

Original Research Articles

Manickavinayaham S, Velez-Cruz R, Biswas AK, Bedford E, Klein BJ, Kutateladze TG, Liu B, Bedford MT, Johnson DG. E2F1 Acetylation Directs p300/CBP-mediated Histone Acetylation at DNA Double-Strand breaks to Facilitate Repair. Nature Communications. Accepted October, 2019; in press).

Ortiz GJ, Li Y, Post SM, Pant V, Xiong S, Larsson CA, El-Naggar AK, Johnson DG, Lozano G.  Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene. 2018 Jan 18;37(3):332-340

Vélez-Cruz R, Johnson DG. The Retinoblastoma (RB) Tumor Suppressor: Pushing Back against Genome Instability on Multiple Fronts.Int J Mol Sci. 2017 Aug 16;18(8). pii: E1776

Domínguez ER, Orona J, Lin K, Pérez CJ, Benavides F, Kusewitt DF, Johnson DG. The p53 R72P polymorphism does not affect the physiological response to ionizing radiation in a mouse model. Cell Cycle. 2017 Jun 18;16(12):1153-1163.

Vélez-Cruz R, Manickavinayaham S, Biswas AK, Clary RW, Premkumar T, Cole F, Johnson DG. RB localizes to DNA double-strand breaks and promotes DNA end resection and homologous recombination through the recruitment of BRG1. Genes Dev. 2016 Nov 15;30(22):2500-2512.

Hossain MB, Shifat R, Johnson DG, Bedford MT, Gabrusiewicz KR, Cortes-Santiago N, Luo X, Lu Z, Ezhilarasan R, Sulman EP, Jiang H, Li SS, Lang FF, Tyler J, Hung MC, Fueyo J, Gomez-Manzano C. TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1. Sci Adv. 2016 Apr 1;2(4):e1501290.

Biswas AK, Mitchell DL, Johnson DG. E2F1 Responds to Ultraviolet Radiation by Directly Stimulating DNA Repair and Suppressing Carcinogenesis. Cancer Res. 2014 Jun 15;74(12):3369-77.

Guan X, Liu Z, Wang L, Johnson DG, Wei Q. Identification of prohibitin and prohibiton as novel factors binding to the p53 induced gene 3 (PIG3) promoter (TGYCC)(15) motif. Biochem Biophys Res Commun. 2014 Jan 24;443(4):1239-44

Perez CJ, Rundhaug JE, Johnson DG, Oberyszyn TM, Tober KL, Kusewitt DF. Slug Expression in Mouse Skin and Skin Tumors Is Not Regulated by p53. J Invest Dermatol 2014 Feb;134(2):566-8.

Sarkar J, Dominguez E, Li G, Kusewitt DF, Johnson DG. Modeling gene-environment interactions in oral cavity and esophageal cancers demonstrates a role for the p53 R72P polymorphism in modulating susceptibility. Mol Carcinog. 2014 Aug;53(8):648-58.

Lu M, Liu Z, Yu H, Wang LE, Li G, Sturgis EM, Johnson DG, Wei Q. Combined effects of E2F1 and E2F2 polymorphisms on risk and early onset of squamous cell carcinoma of the head and neck. Mol Carcinog. 2012 Oct;51 Suppl 1:E132-41.

Valdez CD, Davis JN, Odeh HM, Layfield TL, Cousineau CS, Berton TR, Johnson DG, Wojno KJ, Day ML. Repression of Androgen Receptor Transcription through the E2F1/DNMT1 Axis. PLoS One. 2011;6(9):e25187.

Yu H, Huang YJ, Liu Z, Wang LE, Li G, Sturgis EM, Johnson DG, Wei Q. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. Mol Carcinog. 2011 Sep;50(9):697-706.

Chen J, Zhu F, Weaks RL, Biswas AK, Guo R, Li Y, Johnson DG. E2F1 promotes the recruitment of DNA repair factors to sites of DNA double-strand breaks. Cell Cycle. 2011 Apr 15;10(8):1287-94.

Guo R, Chen J, Mitchell DL, Johnson DG. GCN5 and E2F1 stimulate nucleotide excision repair by promoting H3K9 acetylation at sites of damage. Nucleic Acids Res. 2011 Mar;39(4):1390-7. 

Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White E, Xu J, McDonnell TJ, Shinojima N, Fueyo J. The RB-E2F1 Pathway Regulates Autophagy. Cancer Res. 2010 Oct 15;70(20):7882-93.

Jiang Y, Wang X, Bao S, Guo R, Johnson DG, Shen X, Li L. INO80 chromatin remodeling complex promotes the removal of UV lesions by the nucleotide excision repair pathway. Proc Natl Acad Sci U S A. 2010 Oct 5;107(40):17274-9.

Post SM, Quint_s-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, Lozano G. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 2010 Sep 14;18(3):220-30.

Zhu F, Doll_ ME, Berton TR, Kuiper RV, Capps C, Espejo A, McArthur MJ, Bedford MT, van Steeg H, de Vries A, Johnson DG. Mouse Models for the p53 R72P Polymorphism Mimic Human Phenotypes. Cancer Res. 72010 Jul 15;70(14):5851-9.

Guo R, Chen J, Zhu F, Biswas AK, Berton TR, Mitchell DL, Johnson DG. E2F1 localizes to sites of UV-induced DNA damage to enhance nucleotide excision repair. J Biol Chem. 2010 Jun 18;285(25):19308-15.

Pusapati RV, Weaks RL, Rounbehler RJ, McArthur MJ, Johnson DG. E2F2 suppresses Myc-induced proliferation and tumorigenesis. Mol Carcinog. 2010 Feb;49(2):152-6.

Rojas P, Benavides F, Blando J, Perez C, Cardenas K, Richie E, Knudsen ES, Johnson DG, Senderowicz AM, Rodriguez-Puebla ML, Conti CJ. Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b). Mol Carcinog. 2009 Jun;48(6):508-16.

Paulson QX, Pusapati RV, Hong S, Weaks RL, Conti CJ, Johnson DG. Transgenic expression of E2F3a causes DNA damage leading to ATM-dependent apoptosis. Oncogene. 2008 Aug 21;27(36):4954-61.

Hong SK, Paulson QX, Johnson DG. E2F1 and E2F3 activate ATM through distinct mechanisms to promote E1A-induced apoptosis. Cell Cycle. 2008 Feb 1;7(3):391-400.

Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. 2007 Aug 1;67(15):7212-22.

Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, Aldape KD, Fuller GN, Bekele BN, Yung WK, Gomez-Manzano C, Fueyo J. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res. 2007 May 1;67(9):4005-9.

Russell JL, Weaks RL, Berton TR, Johnson DG. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway. Oncogene. 2006 Feb 9;25(6):867-76.

Paulson QX, McArthur MJ, Johnson DG. E2F3a stimulates proliferation, p53-independent apoptosis and carcinogenesis in a transgenic mouse model. Cell Cycle. 2006 Jan;5(2):184-90.

Pusapati RV, Rounbehler RJ, Hong S, Powers JT, Yan M, Kiguchi K, McArthur MJ, Wong PK, Johnson DG. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1446-51.

Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WK, Gomez-Manzano C. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst. 2005 Nov 2;97(21):1589-600.

Berton TR, Mitchell DL, Guo R, Johnson DG. Regulation of epidermal apoptosis and DNA repair by E2F1 in response to ultraviolet B radiation. Oncogene. 2005 Apr 7;24(15):2449-60.

Rundhaug JE, Hawkins KA, Pavone A, Gaddis S, Kil H, Klein RD, Berton TR, McCauley E, Johnson DG, Lubet RA, Fischer SM, Aldaz CM. SAGE profiling of UV-induced mouse skin squamous cell carcinomas, comparison with acute UV irradiation effects. Mol Carcinog. 2005 Jan;42(1):40-52.

Miliani de Marval PL, Macias E, Rounbehler R, Sicinski P, Kiyokawa H, Johnson DG, Conti CJ, Rodriguez-Puebla ML. Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol. 2004 Sep;24(17):7538-47.

Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res. 2004 Apr;2(4):203-14.

Berton TR, Matsumoto T, Page A, Conti CJ, Deng CX, Jorcano JL, Johnson DG. Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues. Oncogene. 2003 Aug 21;22(35):5415-26.

Wikonkal NM, Remenyik E, Knezevic D, Zhang W, Liu M, Zhao H, Berton TR, Johnson DG, Brash DE. Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice. Nat Cell Biol. 2003 Jul;5(7):655-60.

Rounbehler RJ, Rogers PM, Conti CJ, Johnson DG. Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model. Cancer Res. 2002 Jun 1;62(11):3276-81.

Russell JL, Powers JT, Rounbehler RJ, Rogers PM, Conti CJ, Johnson DG. ARF differentially modulates apoptosis induced by E2F1 and Myc. Mol Cell Biol. 2002 Mar;22(5):1360-8.

Rounbehler RJ, Schneider-Broussard R, Conti CJ, Johnson DG. Myc lacks E2F1's ability to suppress skin carcinogenesis. Oncogene. 2001 Aug 30;20(38):5341-9.

Wang D, Russell J, Xu H, Johnson DG. Deregulated expression of DP1 induces epidermal proliferation and enhances skin carcinogenesis. Mol Carcinog. 2001 Jun;31(2):90-100.

Wang A, Johnson DG, MacLeod MC. Molecular cloning and characterization of a novel mouse epidermal differentiation gene and its promoter. Genomics. 2001 May 1;73(3):284-90.

Zhang SY, Liu SC, Johnson DG, Klein-Szanto AJ. E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines. Cancer Res. 2000 Nov 1;60(21):5972-6..

Wang D, Russell JL, Johnson DG. E2F4 and E2F1 have similar proliferative properties but different apoptotic and oncogenic properties in vivo. Mol Cell Biol. 2000 May;20(10):3417-24.

Wang A, Schneider-Broussard R, Kumar AP, MacLeod MC, Johnson DG. Regulation of BRCA1 expression by the Rb-E2F pathway. J Biol Chem. 2000 Feb 11;275(6):4532-6.

Wang A, Pierce A, Judson-Kremer K, Gaddis S, Aldaz CM, Johnson DG, MacLeod MC. Rapid analysis of gene expression (RAGE) facilitates universal expression profiling. Nucleic Acids Res. 1999 Dec 1;27(23):4609-18.

Pierce AM, Schneider-Broussard R, Gimenez-Conti IB, Russell JL, Conti CJ, Johnson DG. E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol Cell Biol. 1999 Sep;19(9):6408-14.

Rodriguez-Puebla ML, LaCava M, Gimenez-Conti IB, Johnson DG, Conti CJ. Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin. Oncogene. 1998 Oct 29;17(17):2251-8.

Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG. Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8858-63.

Pierce AM, Schneider-Broussard R, Philhower JL, Johnson DG. Differential activities of E2F family members: unique functions in regulating transcription. Mol Carcinog. 1998 Jul;22(3):190-8..

Pierce AM, Fisher SM, Conti CJ, Johnson DG. Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene. 1998 Mar 12;16(10):1267-76.

Rodriguez-Puebla ML, Robles AI, Johnson DG, LaCava M, Conti CJ. Synchronized proliferation induced by 12-O-tetradecanoylphorbol-13-acetate treatment of mouse skin: an in vivo model for cell cycle regulation. Cell Growth Differ. 1998 Jan;9(1):31-9.

Johnson DG, Coleman A, Powell KL, MacLeod MC. High-affinity binding of the cell cycle-regulated transcription factors E2F1 and E2F4 to benzo[a]pyrene diol epoxide-DNA adducts. Mol Carcinog. 1997 Oct;20(2):216-23.

Butler AP, Johnson DG, Kumar AP, Narayan S, Wilson SH, MacLeod MC. Disruption of transcription in vitro and gene expression in vivo by DNA adducts derived from a benzo[a]pyrene diol epoxide located in heterologous sequences. Carcinogenesis. 1997 Feb;18(2):239-44.

Johnson DG. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Oncogene. 1995 Nov 2;11(9):1685-92.

Johnson DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12823-7.

Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 1994 Jul 1;8(13):1514-25.

Cress WD, Johnson DG, Nevins JR. A genetic analysis of the E2F1 gene distinguishes regulation by Rb, p107, and adenovirus E4. Mol Cell Biol. 1993 Oct;13(10):6314-25.

Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993 Sep 23;365(6444):349-52.

Cooper C, Johnson D, Roman C, Avitahl N, Tucker P, Calame K. The C/EBP family of transcriptional activators is functionally important for Ig VH promoter activity in vivo and in vitro. 1992 Nov 15;149(10):3225-31.

Johnson DG, Carayannopoulos L, Capra JD, Tucker PW, Hanke JH. The ubiquitous octamer-binding protein(s) is sufficient for transcription of immunoglobulin genes. Mol Cell Biol. 1990 Mar;10(3):982-90.

Invited Articles

Johnson, DG and Dent, SY. Chromatin: receiver and quarterback for cellular signals. Cell. 2013 Feb 14;152(4):685-9. 

Vélez-Cruz, R. and Johnson, DG.  E2F1 and p53 Transcription Factors as Accessory Factors for Nucleotide Excision Repair. Int J Mol Sci. 2012 Oct 19;13(10):13554-68.

Biswas AK, Johnson DG. Transcriptional and Nontranscriptional Functions of E2F1 in Response to DNA Damage. Cancer Res. 2012 Jan 1;72(1):13-7.

Johnson DG, Degregori J. Putting the oncogenic and tumor suppressive activities of E2F into context. Curr Mol Med. 2006 Nov;6(7):731-8.

DeGregori J, Johnson DG. Distinct and overlapping roles for E2F family members in transcription, proliferation, and apoptosis. Curr Mol Med. 2006 Nov;6(7):739-48.

Hong S, Pusapati RV, Powers JT, Johnson DG. Oncogenes and the DNA damage response: Myc and E2F1 engage the ATM signaling pathway to activate p53 and induce apoptosis. Cell Cycle. 2006 Apr;5(8):801-3.

Johnson DG, Rogers PM. E2F murine models of human carcinogenesis. Recent Res Dev Mol Cell Biol. 2002 3(2):455-70, 2002.

Johnson DG. The paradox of E2F1: oncogene and tumor suppressor gene. Mol Carcinog. 2000 Mar;27(3):151-7.

Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295-312.

Johnson DG, Schneider-Broussard R. Role of E2F in cell cycle control and cancer. Front Biosci. 1998 Apr 27;3:d447-8.

Johnson DG, Richie ER, Conti CJ. The cell cycle and cancer. Cancer Bull. 1995;47:480-5.